Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Net Margin (2018 - 2023)

Denali Therapeutics has reported Net Margin over the past 6 years, most recently at 7841.59% for Q3 2023.

  • Quarterly Net Margin fell 493912.0% to 7841.59% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 33121.86% through Jun 2024, down 3308442.0% year-over-year, with the annual reading at 43.94% for FY2023, 25662.0% up from the prior year.
  • Net Margin was 7841.59% for Q3 2023 at Denali Therapeutics, down from 62.35% in the prior quarter.
  • Over five years, Net Margin peaked at 77.27% in Q4 2020 and troughed at 7004100.0% in Q1 2021.
  • The 5-year median for Net Margin is 986.78% (2022), against an average of 380463.11%.
  • Year-over-year, Net Margin tumbled -700250096bps in 2021 and then surged 700394220bps in 2022.
  • A 5-year view of Net Margin shows it stood at 1236.26% in 2019, then skyrocketed by 106bps to 77.27% in 2020, then plummeted by -878bps to 601.41% in 2021, then plummeted by -64bps to 986.78% in 2022, then plummeted by -695bps to 7841.59% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Net Margin are 7841.59% (Q3 2023), 62.35% (Q2 2023), and 312.4% (Q1 2023).